BTIG Research cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a neutral rating in a research note published on Thursday morning, Marketbeat reports. The brokerage currently has $24.00 price objective on the stock. The analysts noted that the move was a valuation call.

Other research analysts have also recently issued reports about the company. Piper Jaffray Companies set a $16.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Thursday, December 14th. BidaskClub cut Teva Pharmaceutical Industries from a sell rating to a strong sell rating in a research report on Thursday, September 21st. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Wednesday, January 3rd. Royal Bank of Canada upped their price objective on Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the stock an underperform rating in a research report on Sunday, November 5th. Finally, Leerink Swann assumed coverage on Teva Pharmaceutical Industries in a research report on Tuesday, January 2nd. They set an underperform rating and a $15.00 price objective for the company. Eight investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $21.32.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $20.70 on Thursday. The stock has a market capitalization of $20,640.00, a PE ratio of -3.53, a PEG ratio of 1.48 and a beta of 0.54. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $37.94. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. equities research analysts predict that Teva Pharmaceutical Industries will post 3.74 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Capital Research Global Investors increased its position in Teva Pharmaceutical Industries by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. FMR LLC increased its position in Teva Pharmaceutical Industries by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Macquarie Group Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after acquiring an additional 3,429,448 shares during the period. Capital World Investors grew its holdings in shares of Teva Pharmaceutical Industries by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after acquiring an additional 3,268,200 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 62.5% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,775,753 shares of the company’s stock worth $191,861,000 after acquiring an additional 2,221,695 shares during the period. Institutional investors own 51.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Lowered to “Neutral” at BTIG Research” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/21/teva-pharmaceutical-industries-teva-lowered-to-neutral-at-btig-research.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.